**Andersson 1990** Andersson T, Regårdh CG. Pharmacokinetics of Omeprazole and Metabolites Following Single Intravenous and Oral Doses of 40 and 80mg. *Drug Investig*. 1990;2(4):255-263.

**Andersson 1991** Andersson T, Cederberg C, Heggelund A, Lundborg P. The Pharmacokinetics of Single and Repeated Once-Daily Doses of 10, 20 and 40mg Omeprazole as Enteric-Coated Granules. *Drug Investig*. 1991;3(1):45-52.

**Andersson 1998** Andersson T, Holmberg J, Röhss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. *Br J Clin Pharmacol*. 1998;45(4):369-375.

**Andersson 2000** Andersson T, Rohss K, Hassan-alin M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). *Gastroenterology*. 118(4):A1210

**Äbelö 2000** Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. *Drug Metab Dispos*. 2000;28(8):966-972.

**NCT01983566** Investigation of the effect of food and of increased gastric pH on the relative bioavailability of deleobuvir following single oral administration in healthy Caucasian and Japanese subjects (an open label, randomised, four-way crossover study)

**Cho 2002** Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic em genotype for CYP2C19. *Br J Clin Pharmacol*. 2002;53(4):393-397.

**DrugBank DB00176** (https://www.drugbank.ca/drugs/DB00176)

**FDA Nexium Review** FDA – Clinical Pharmacology and Biopharmaceutics Review – Nexium delayed-Release Capsules – Esomeprazole sodium – Application number 21-153/21-154

**FDA SPC** FDA_ClinPharmReview LuvoxCR, NDA 22-033, FDADrug_42.pdf, website: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022033s000_ClinPharmR.pdf

**Galetin and Houston 2006** Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. *J Pharmacol Exp Ther*. 2006;318(3):1220-1229. 

**Hassan-Alin 2000** Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. *Eur J Clin Pharmacol*. 2000;56(9-10):665-670.

**Hassan-Alin 2005** Hassan-Alin M, Andersson T, Niazi M, Röhss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. *Eur J Clin Pharmacol*. 2005;60(11):779-784

**Nexium prescribing information** Website: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Liu 2005** Liu KH, Kim MJ, Shon JH, et al. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. *Xenobiotica*. 2005;35(1):27-38

**Ogilvie 2011** Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. *Drug Metab Dispos.* 2011;39(11):2020–33.

**Olivares-Morales 2016**  Olivares-Morales A, Ghosh A, Aarons L, Rostami-Hodjegan A. Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS(R) Formulation of Oxybutynin. *AAPS J*. 2016;18(6):1532-1549. 

**Oosterhuis 1992** Oosterhuis B, Jonkman JHG, Andersson T, Zuiderwijk PBM. No influence of single intravenous doses of omeprazole on theophylline elimination kinetics. *J Clin Pharmacol*. 1992;32(5):470-475.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Regårdh 1990** Regårdh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. *Ther Drug Monit*. 1990;12(2):163-172.

**Röhss 2007** Röhss, K., Wilder-Smith, C., Kilhamn, J., Fjellman, M. & Lind, T. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects. *CP* **45**, 345–354 (2007).

**Uno 2007** Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. *Eur J Clin Pharmacol*. 2007;63(2):143-149.

**Wilder-Smith 2005** Wilder-Smith CH, Bondarov P, Lundgren M, et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: Results of two randomized clinical studies. *Eur J Gastroenterol Hepatol*. 2005;17(2):191-197

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.

**Wu 2014** Wu F, Gaohua L, Zhao P, Jamei M, Huang S-M, Bashaw ED, et al. Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions. *Pharmaceutical Research*. 2014 Aug;31(8):1919–29.

**Wu 2016** Wu, J., Gießmann, T., Lang, B., Elgadi, M. & Huang, F. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. *J Pharm Pharmacol* **68**, 459–466 (2016).

**Yasui-Furukori 2004** Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. *Br J Clin Pharmacol*. 2004;57(4):487-494.